Stephen D. Dickson1, Esad Vucic1,2, Claudia Calcagno1, James HF Rudd1, James Lin1, Jessica Mounessa1, Michelle Roytman1, Zahi A. Fayad1,2
1Radiology, Mount Sinai School of Medicine, New York, NY, United States; 2Medicine, Mount Sinai School of Medicine, New York, NY, United States
Dynamic contrast enhanced (DCE) MRI and F18-fluorodeoxyglucose (FDG) PET/CT was performed on control and pioglitazone-treated atherosclerotic New Zealand White Rabbits at three time points over three months. After three months, treated animals showed decreased MRI contrast agent uptake in plaque as well as decreased FDG signal as compared to controls. Macrophage specific immuno-histochemistry validated anti-inflammatory observations.